Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1A | P48039 | 7/20 | 0.61 |
| ▸ | MTNR1B | P49286 | 7/20 | 0.61 |
| ▸ | NPC1 | O15118 | 3/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CPA1 | P15085 | 3/20 | 0.42 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.41 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 3/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.40 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.39 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1986644 | 0.84 | NPC1 (0.56) | MTNR1AMTNR1BNPC1ALDH1A1CPA1 | |
| SCHEMBL1984199 | 0.81 | MTNR1A (0.40) | MTNR1AMTNR1BNPC1ALDH1A1CYP3A4 | |
| SCHEMBL27165021 | 0.80 | KMT2A (0.49) | MTNR1AMTNR1BNPC1ALDH1A1CYP3A4 | |
| SCHEMBL9753033 | 0.80 | KMT2A (0.49) | MTNR1AMTNR1BNPC1ALDH1A1CYP3A4 | |
| SCHEMBL809523 | 0.80 | KMT2A (0.49) | MTNR1AMTNR1BNPC1ALDH1A1CYP3A4 | |
| SCHEMBL3782099 | 0.79 | MTNR1A (0.71) | MTNR1AMTNR1BNPC1BCAT2MEN1 | |
| SCHEMBL4788685 | 0.78 | NPC1 (0.55) | NPC1ALDH1A1CYP3A4CPA1ADAM17 | |
| SCHEMBL28344702 | 0.78 | KMT2A (0.42) | MTNR1AMTNR1BNPC1ALDH1A1CYP3A4 | |
| SCHEMBL1985542 | 0.78 | MTNR1A (0.69) | MTNR1AMTNR1BNPC1BCAT2 | |
| SCHEMBL14361142 | 0.76 | MTNR1A (0.67) | MTNR1AMTNR1BALDH1A1BCAT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2055689-B1 | Method for producing an optically active nitro compound | SUMITOMO CHEMICAL CO (JP) | 2011-06-29 | — | — | EP | disclosed |
| US-7790900-B2 | Method for producing an optically active nitro compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2010-09-07 | — | — | US | disclosed |
| EP-2055689-A1 | Method for producing an optically active nitro compound | Sumitomo Chemical Company, Limited (JP) | 2009-05-06 | — | — | EP | disclosed |
| EP-1641740-B1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE NITRO COMPOUND | SUMITOMO CHEMICAL CO (JP) | 2009-03-25 | — | — | EP | disclosed |
| US-20070037976-A1 | such as 1-amino-2-phenylpropane by reacting unsaturated nitroolefin with organosilicon compounds such as poly(methylhydrosiloxane) and phenylsilane, in presence of asymmetric copper complex having phosphine ligand | SUMITOMO CHEMICAL COMPANY, LIMITED ERICK M. CARREIRA | 2007-02-15 | — | — | US | disclosed |
| EP-1641740-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE NITRO COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-04-05 | — | — | EP | disclosed |
| WO-2004103951-A1 | METHOD FOR PRODUCING AN OPTICALLY ACTIVE NITRO COMPOUND | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2004-12-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070037976-A1 | such as 1-amino-2-phenylpropane by reacting unsaturated nitroolefin with organosilicon compounds such as poly(methylhydrosiloxane) and phenylsilane, in presence of asymmetric copper complex having phosphine ligand | L1CAM, SPATS2L, AAAS | MTNR1A 3535/4885MTNR1B 3691/4885NPC1 2046/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.